Drug Trial Radar · NCT04673617
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Mar 29, 2021
Primary completion
Oct 6, 2025
Study completion Oct 6, 2025
Sponsor
- Lead sponsor
- Artiva Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients. Patients will be assigned to receive either AB-101 alone as monotherapy, in combination with rituximab (including DLBCL specific cohort) or in combination with bendamustine and rituximab. All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and tumor response. Patients receiving AB-101 in combination with rituximab may receive up to 3 additional cycles of treatment. Patients receiving AB-101 in combination with bendamustine and rituximab may receive up to 5 additional cycles of treatment. Patients enrolled into the DLBCL specific cohort receiving AB-101 in combination with rituximab may receive up to 3 cycles of treatment.
Conditions
- Non Hodgkin Lymphoma
Interventions
AB-101Drug
NK cell therapy
RituximabDrug
Anti-CD20 antibody therapy
Interleukin-2Drug
Immune cytokine
CyclophosphamideDrug
Lymphodepleting chemotherapy
FludarabineDrug
Lymphodepleting chemotherapy
BendamustineDrug
Chemoimmunotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Safety and tolerability of AB-101 as monotherapy, and in combination with rituximab (including the DLBCL specific cohort) and in combination with bendamustine and rituximab.Time frame: From the ICF signature through 13 weeks after last study drug dose.
- Phase 1, combination therapy: AB-101 clinical activity, determined by ORRTime frame: From baseline disease assessment through end of study participation.
- Phase 1, combination therapy: Identify the recommended Phase 2 dose (R2PD) for AB-101.Time frame: From ICF signature through 13 weeks after last study drug dose.
- Phase 2: Determine the efficacy profile of AB-101 in combination with rituximab or in combination with bendamustine and rituximab when administered to patients with R/R NHL of B-cell origin.Time frame: From baseline disease assessment through end of study participation.
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Artiva Clinical Trial Site
Birmingham, Alabama
Artiva Clinical Trial Site
Tucson, Arizona
Artiva Clinical Trial Site
Orange, California
Artiva Clinical Trial Site
San Diego, California
Artiva Clinical Trial Site
Gainesville, Florida
Artiva Clinical Trial Site
Atlanta, Georgia
Artiva Clinical Trial Site
Chicago, Illinois
Artiva Clinical Trial Site
Iowa City, Iowa
Artiva Clinical Trial Site
Wichita, Kansas
Artiva Clinical Trial Site
Louisville, Kentucky
Artiva Clinical Trial Site
Detroit, Michigan
Artiva Clinical Trial Site
Lake Success, New York
Artiva Clinical Trial Site
New York, New York
Artiva Clinical Trial Site
Columbus, Ohio
Artiva Clinical Trial Site
Portland, Oregon
Artiva Clinical Trial Site
Philadelphia, Pennsylvania
Artiva Clinical Trial Site
Philadelphia, Pennsylvania
Artiva Clinical Trial Site
Providence, Rhode Island
Artiva Clinical Trial Site
Dallas, Texas
Artiva Clinical Trial Site
Salt Lake City, Utah
Artiva Clinical Trial Site
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.